Voyager Therapeutics Inc
Closed
3.33 -7.5
Overview
Share price change
24h
Min
3.3
Max
3.35
Income | -511K -28M |
|---|---|
Sales | -13M 2.6M |
EPS | -0.47 |
Profit margin | -1,077.401 |
Employees | 141 |
EBITDA | -455K -29M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +354.65% upside |
Next Earnings | 4 sie 2026 |
|---|
Market Cap | -5.4M 229M |
|---|---|
Previous open | 10.83 |
Previous close | 3.33 |
Voyager Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Voyager Therapeutics Inc Forecast
Price Target
By TipRanks
354.65% upside
12 Months Forecast
Average 15.14 USD 354.65%
High 25 USD
Low 8 USD
Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
